$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[해외논문] Structure-based glycoengineering of interferon lambda 4 enhances its productivity and anti-viral potency 원문보기

Cytokine, v.125, 2020년, pp.154833 -   

Chung, Jae-Hee (Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST)) ,  Hong, Seon-Hui (Biomedical Science and Engineering Interdisciplinary Program, Korea Advanced Institute of Science and Technology (KAIST)) ,  Seo, Nari (Graduate School of Analytical Science & Technology, Chungnam National University) ,  Kim, Tae-Shin (Graduate School of Medical Science & Engineering, Korea Advanced Institute of Science and Technology (KAIST)) ,  An, Hyun Joo (Graduate School of Analytical Science & Technology, Chungnam National University) ,  Lee, Pedro (Graduate School of Medical Science & Engineering, Korea Advanced Institute of Science and Technology (KAIST)) ,  Shin, Eui-Cheol (Biomedical Science and Engineering Interdisciplinary Program, Korea Advanced Institute of Science and Technology (KAIST)) ,  Kim, Ho Min (Biomedical)

Abstract ▼ AI-Helper 아이콘AI-Helper

Abstract Interferon lambda 4 (IFNλ4) has been recently known and studied for its role in hepatitis C virus (HCV) infection, but its clinical potential is significantly hampered due to its poor expression in vitro. Our study reports the successful production of IFNλ4 from a mammalian c...

Keyword

#IFNλ4   #Glycoengineering   #Homology modeling   #Type III interferon signaling   #Anti-viral activity  

참고문헌 (44)

  1. 1 Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling Nat. Rev. Immunol. 5 2005 375 386 15864272 

    상세보기

  2. 2 McNab F. Mayer-Barber K. Sher A. Wack A. O'Garra A. Type I interferons in infectious disease Nat. Rev. Immunol. 15 2015 87 103 25614319 

    상세보기

  3. 3 Wack A. Terczynska-Dyla E. Hartmann R. Guarding the frontiers: the biology of type III interferons Nat Immunol 16 2015 802 809 26194286 

    상세보기

  4. 4 Kotenko S.V. Durbin J.E. Contribution of type III interferons to antiviral immunity: location, location, location J. Biol. Chem. 292 2017 7295 7303 28289095 

    상세보기

  5. 5 Lasfar A. Zloza A. Cohen-Solal K.A. IFN-lambda therapy: current status and future perspectives Drug Discovery Today 21 2016 167 171 26552337 

    상세보기

  6. 6 Andreakos E. Zanoni I. Galani I.E. Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control Curr. Opin. Immunol. 56 2019 67 75 30399529 

    상세보기

  7. 7 Kotenko S.V. Gallagher G. Baurin V.V. Lewis-Antes A. Shen M. Shah N.K. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex Nat. Immunol. 4 2003 69 77 12483210 

  8. 8 Sheppard P. Kindsvogel W. Xu W. Henderson K. Schlutsmeyer S. Whitmore T.E. IL-28, IL-29 and their class II cytokine receptor IL-28R Nat. Immunol. 4 2003 63 68 12469119 

    상세보기

  9. 9 Prokunina-Olsson L. Muchmore B. Tang W. Pfeiffer R.M. Park H. Dickensheets H. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus Nat. Genet. 45 2013 164 171 23291588 

    상세보기

  10. 10 Terczynska-Dyla E. Bibert S. Duong F.H. Krol I. Jorgensen S. Collinet E. Reduced IFNlambda4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes Nat. Commun. 5 2014 5699 25534433 

  11. 11 Hamming O.J. Terczynska-Dyla E. Vieyres G. Dijkman R. Jorgensen S.E. Akhtar H. Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses EMBO J. 32 2013 3055 3065 24169568 

  12. 12 Song K. Yoon I.S. Kim N.A. Kim D.H. Lee J. Lee H.J. Glycoengineering of interferon-beta 1a improves its biophysical and pharmacokinetic properties PLoS ONE 9 2014 e96967 

    상세보기

  13. 13 Ceaglio N. Etcheverrigaray M. Kratje R. Oggero M. Novel long-lasting interferon alpha derivatives designed by glycoengineering Biochimie 90 2008 437 449 18039474 

    상세보기

  14. 14 Sagt C.M. Kleizen B. Verwaal R. de Jong M.D. Muller W.H. Smits A. Introduction of an N-glycosylation site increases secretion of heterologous proteins in yeasts Appl. Environ. Microbiol. 66 2000 4940 4944 11055947 

    상세보기

  15. 15 Liu Y. Nguyen A. Wolfert R.L. Zhuo S. Enhancing the secretion of recombinant proteins by engineering N-glycosylation sites Biotechnol. Prog. 25 2009 1468 1475 19637381 

    상세보기

  16. 16 Hua S. Hu C.Y. Kim B.J. Totten S.M. Oh M.J. Yun N. Glyco-analytical multispecific proteolysis (Glyco-AMP): a simple method for detailed and quantitative Glycoproteomic characterization J. Proteome Res. 12 2013 4414 4423 24016182 

    상세보기

  17. 17 An H.J. Tillinghast J.S. Woodruff D.L. Rocke D.M. Lebrilla C.B. A new computer program (GlycoX) to determine simultaneously the glycosylation sites and oligosaccharide heterogeneity of glycoproteins J. Proteome Res. 5 2006 2800 2808 17022651 

    상세보기

  18. 18 Sung P.S. Cheon H. Cho C.H. Hong S.H. Park D.Y. Seo H.I. Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness Proc. Natl. Acad. Sci. U S A 112 2015 10443 10448 26216956 

    상세보기

  19. 19 Kang W. Shin E.C. Colorimetric focus-forming assay with automated focus counting by image analysis for quantification of infectious hepatitis C virions PLoS ONE 7 2012 e43960 

    상세보기

  20. 20 Sung P.S. Murayama A. Kang W. Kim M.S. Yoon S.K. Fukasawa M. Hepatitis C virus entry is impaired by claudin-1 downregulation in diacylglycerol acyltransferase-1-deficient cells J. Virol. 88 2014 9233 9244 24899196 

    상세보기

  21. 21 Gad H.H. Dellgren C. Hamming O.J. Vends S. Paludan S.R. Hartmann R. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family J. Biol. Chem. 284 2009 20869 20875 19457860 

  22. 22 Miknis Z.J. Magracheva E. Li W. Zdanov A. Kotenko S.V. Wlodawer A. Crystal structure of human interferon-lambda1 in complex with its high-affinity receptor interferon-lambdaR1 J. Mol. Biol. 404 2010 650 664 20934432 

  23. 23 Mendoza J.L. Schneider W.M. Hoffmann H.H. Vercauteren K. Jude K.M. Xiong A. The IFN-lambda-IFN-lambdaR1-IL-10Rbeta Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity Immunity 46 2017 379 392 28329704 

  24. 24 Chavan M. Lennarz W. The molecular basis of coupling of translocation and N-glycosylation Trends Biochem. Sci. 31 2006 17 20 16356726 

    상세보기

  25. 25 Kornfeld R. Kornfeld S. Assembly of asparagine-linked oligosaccharides Annu. Rev. Biochem. 54 1985 631 664 3896128 

    상세보기

  26. 26 Oh M.J. Hua S. Kim U. Kim H.J. Lee J. Kim J.H. Analytical detection and characterization of biopharmaceutical glycosylation by MS Bioanalysis 8 2016 711 727 26964748 

    상세보기

  27. 27 Sung P.S. Hong S.H. Chung J.H. Kim S. Park S.H. Kim H.M. IFN-lambda4 potently blocks IFN-alpha signalling by ISG15 and USP18 in hepatitis C virus infection Sci. Rep. 7 2017 3821 28630501 

  28. 28 Schoggins J.W. Rice C.M. Interferon-stimulated genes and their antiviral effector functions Curr. Opin. Virol. 1 2011 519 525 22328912 

    상세보기

  29. 29 Obajemu A.A. Rao N. Dilley K.A. Vargas J.M. Sheikh F. Donnelly R.P. IFN-lambda4 attenuates antiviral responses by enhancing negative regulation of IFN signaling J. Immunol. 199 2017 3808 3820 29070670 

  30. 30 Sinclair A.M. Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins J. Pharm. Sci. 94 2005 1626 1635 15959882 

    상세보기

  31. 31 Kelleher D.J. Gilmore R. An evolving view of the eukaryotic oligosaccharyltransferase Glycobiology 16 2006 47R 62R 

    상세보기

  32. 32 Chennamsetty N. Voynov V. Kayser V. Helk B. Trout B.L. Design of therapeutic proteins with enhanced stability Proc. Natl. Acad. Sci. U S A 106 2009 11937 11942 19571001 

    상세보기

  33. 33 Roberts C.J. Therapeutic protein aggregation: mechanisms, design, and control Trends Biotechnol. 32 2014 372 380 24908382 

  34. 34 Bai L. Wang T. Zhao G. Kovach A. Li H. The atomic structure of a eukaryotic oligosaccharyltransferase complex Nature 555 2018 328 333 29466327 

  35. 35 Braunger K. Pfeffer S. Shrimal S. Gilmore R. Berninghausen O. Mandon E.C. Structural basis for coupling protein transport and N-glycosylation at the mammalian endoplasmic reticulum Science 360 2018 215 219 29519914 

    상세보기

  36. 36 Wild R. Kowal J. Eyring J. Ngwa E.M. Aebi M. Locher K.P. Structure of the yeast oligosaccharyltransferase complex gives insight into eukaryotic N-glycosylation Science 359 2018 545 550 29301962 

    상세보기

  37. 37 Quesada J.R. Hersh E.M. Manning J. Reuben J. Keating M. Schnipper E. Treatment of hairy cell leukemia with recombinant alpha-interferon Blood 68 1986 493 497 3730612 

    상세보기

  38. 38 Stadler R. Luger T. Bieber T. Kohler U. Linse R. Technau K. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial Acta Oncol. 45 2006 389 399 16760174 

    상세보기

  39. 39 Volberding P.A. Mitsuyasu R.T. Golando J.P. Spiegel R.J. Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A) Cancer 59 1987 620 625 3492260 

  40. 40 Mazdeh M. Afzali S. Jaafari M.R. The therapeutic effect of Avonex, Rebif and Betaferon on EDSS and relapse in multiple sclerosis: a comparative study Acta Medica Iranica 48 2010 83 88 21132998 

    상세보기

  41. 41 Sanford M. Lyseng-Williamson K.A. Subcutaneous recombinant interferon-beta-1a (Rebif(R)): a review of its use in the treatment of relapsing multiple sclerosis Drugs 71 2011 1865 1891 21942977 

  42. 42 Pakdaman H. Abbasi M. Gharagozli K. Ashrafi F. Delavar Kasmaei H. Amini Harandi A. A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis Neurol. Sci.: Official J. Italian Neurol. Soc. Italian Soc. Clin. Neurophysiol. 39 2018 2107 2113 

  43. 43 Peginterferon beta-1a (Plegridy) for multiple sclerosis. The Medical letter on drugs and therapeutics 2015; 57: pp. 67？9. 

  44. 44 Davidson S. McCabe T.M. Crotta S. Gad H.H. Hessel E.M. Beinke S. IFNlambda is a potent anti-influenza therapeutic without the inflammatory side effects of IFNalpha treatment EMBO Mol. Med. 8 2016 1099 1112 27520969 

LOADING...

활용도 분석정보

상세보기
다운로드
내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

관련 콘텐츠

오픈액세스(OA) 유형

GREEN

저자가 공개 리포지터리에 출판본, post-print, 또는 pre-print를 셀프 아카이빙 하여 자유로운 이용이 가능한 논문

유발과제정보 저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로